Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma
This study evaluates the efficacy and safety of PBI-05204, an extract of the leaves of Nerium oleander, in patients with Stage IV metastatic pancreatic cancer. All patients will receive PBI-05204.
Pancreatic Cancer
DRUG: PBI 05204
overall survival, 4.5 months
Time to Progression, up to 1 year|Time to Treatment Failure, up to 1 year|Progression free survival, up to 1 year|Overall response rate, up to 1 year|Tumor control rate, up to 1 year|Duration of response, up to 1 year|CA 19-9 response, up to 1 year
This study evaluates the efficacy and safety of PBI-05204, an extract of the leaves of Nerium oleander, in patients with Stage IV metastatic pancreatic cancer. All patients will receive PBI-05204.